Kerr S H, Kerr D J
Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road Campus, Off Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom.
Cancer Lett. 2009 Dec 1;286(1):114-20. doi: 10.1016/j.canlet.2009.07.001. Epub 2009 Aug 6.
Hepatocellular cancer (HCC) has always been considered a therapeutic challenge, given the cytoxic drug resistant nature of the cancer and associated disorder in liver function, reducing the safety of many conventional chemotherapy agents. The Multikinase inhibitor sorafenib has been found to prolong survival in patients with advanced HCC, by around 3months compared to placebo, but novel treatments need to be explored. Current experimental therapeutic approaches encompass a broad range of science, ranging from intrahepatic irradiation to virus directed immunotherapy. This chapter presents a horizon scan of novel treatments which are currently at early stages of trial development.
鉴于肝细胞癌（HCC）具有抗细胞毒性药物的特性以及相关的肝功能紊乱，降低了许多传统化疗药物的安全性，它一直被视为治疗上的挑战。多激酶抑制剂索拉非尼已被发现可延长晚期HCC患者的生存期，与安慰剂相比延长约3个月，但仍需要探索新的治疗方法。当前的实验性治疗方法涵盖了广泛的科学领域，从肝内照射到病毒导向免疫疗法。本章对目前正处于试验开发早期阶段的新治疗方法进行了前瞻性扫描。
